Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2005-03-31
2010-06-22
Saunders, David A (Department: 1644)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C536S023400, C536S023500
Reexamination Certificate
active
07741078
ABSTRACT:
A heparin-binding protein having covalently bonded heparan sulfate sugar chains within its molecule is produced by ligating a cDNA encoding a peptide which can be modified with heparan sulfate sugar chains selectively to a cDNA encoding a heparin-binding protein and producing in an animal cell the gene product of the resultant ligated cDNA. This heparan sulfate sugar chain-modified heparin-binding protein is functionalized by covalently bonding thereto glycosaminoglycan sugar chains containing little chondroitin sulfate. For example, this heparin-binding protein is excellent in stabilities, such as thermostability, acid resistance, alkali resistance and in vivo stability. Further, the heparan sulfate sugar chain-modified heparin-binding protein is effective in cell proliferation and tissue regeneration, and has effect of regulating the physiological functions of FGFs. Thus, this heparin-binding protein is extremely useful as a medicine for preventing or treating various FGF-related diseases.
REFERENCES:
patent: 5486599 (1996-01-01), Saunders et al.
patent: 2003/0100492 (2003-05-01), Yayon
patent: 2006/0079451 (2006-04-01), Imamura et al.
patent: 11-137255 (1999-05-01), None
patent: 11-137255 (1999-05-01), None
International Preliminary Report on Patentability for International application No. PCT/JP2005/006364 issued Oct. 19, 2006.
International Search Report for International Application PCT/JP2005/006364 mailed Jun. 7, 2005.
M. Asada et al., Modification of FGF-1, preferentially with heparan sulfate but not chondroitin sulfate, Seikagaku, 76 (8), Aug. 25, 2004, p. 1006.
A. Yoneda et al., Engineering of an FGF-proteoglycan fusion protein with heparin-independent, mitogenic activity, Nat Biotechnol, 18(6), 2000, pp. 641 to 644.
Examination Report for 0B0621466.2, dated Oct. 22, 2007.
Office Action No. 652525 issued on Japanese Patent application No. 2004-108570, mailed Oct. 28, 2008.
Office Action No. 130437 issued on Japanese Patent Application No. 2004-108570, mailed Mar. 3, 2009.
Office Acton issued on UK Patent Application No. 0621466.2 on Jun. 27, 2008.
Office Action issued on UK Patent Application No. 0621466.2 on Sep. 12, 2008.
Office Action issued on UK Patent Application No. 0621466.2 on Oct. 2, 2008.
Asada Masahiro
Imamura Toru
Suzuki Masashi
Hogan & Hartson LLP
National Institute of Advanced Science and Technology
Saunders David A
LandOfFree
Heparin-binding protein modified with heparan sulfate sugar... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heparin-binding protein modified with heparan sulfate sugar..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heparin-binding protein modified with heparan sulfate sugar... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4242488